Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · GREELEY, CO · NPI 1790309318
Verified facts
CMS Open Payments records show Corey Andrew Jones, DO received $24.32 in general payments during 2025 across 1 reported records.
Edwards Lifesciences Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.32 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $24.32 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $24.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 161 | 52 |
| Lisinopril | Lisinopril | 154 | 60 |
| Losartan Potassium | Losartan Potassium | 137 | 50 |
| Omeprazole | Omeprazole | 113 | 41 |
| Metformin Hcl Er | Metformin Hcl | 109 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 38 |
| Gabapentin | Gabapentin | 98 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 86 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 28 |
| Metformin Hcl | Metformin Hcl | 63 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 27 |
| Simvastatin | Simvastatin | 60 | 22 |
| Furosemide | Furosemide | 53 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 18 |
| Famotidine | Famotidine | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 14 |
| Tramadol Hcl | Tramadol Hcl | 45 | 25 |
| Allopurinol | Allopurinol | 44 | 15 |
| Meloxicam | Meloxicam | 36 | 15 |
| Prednisone | Prednisone | 35 | 28 |
| Sertraline Hcl | Sertraline Hcl | 35 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 13 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | 12 |
| Eliquis | Apixaban | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 22 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24.32 · 1 records | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error